How NovoLog® Works

  1. NovoLog® Prescribing Information. Verson 22; April 2014. Novo Nordisk Inc., Plainsboro, NJ.
  2. Types of insulin. University of California-San Fransicio (UCFS) Diabetes Education. http://dtc.ucsf.edu/types-of-diabetes/type1/treatment-of-type-1-diabetes/medications-and-therapies/type-1-insulin-therapy/types-of-insulin/. Accessed June 12, 2014.
  3. Lindholm A, McEwen J, Riis AP. Imporoved postparandial glycemic control with insulin aspart: a randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care. 1999;22(5):801-805.
  4. American Diabetes Association. Type 1 diabetes. http://diabetes.org/diabetes-basics/type-1/?loc=db-slabnav. Accessed June 14, 2014.
  5. Campbell NA. Biology. Fourth Ed. Chapter 41 Chemical Signals in Animals. The Benjamin/ Cummings Publishing Company. Menlo Park California: 1996.
  6. Living Well, a Diabetes Care Handbook, Intermountain Healthcare. 2009 Edition. http://intermountainhealthcare.org/ext/Dcmnt?ncid=51081386. Accessed June 10, 2014.
  7. American Diabetes Assoication. Common terms: F-K. http://diabetes.org/diabetes-basics/common-terms/common-terms-f-k.html. Accessed June 14, 2014.
  8. Scheiner G, Sobel RJ, Smith DE, et al. Insulin pump therapy: guidelines for successful outcomes. Presented at American Association of Diabetes Educators 2008 Consensus Summit, September 18, 2008, Chicago, Illinois.
  9. Diabetes.co.uk. Basal bolus: Basal bolus injection regimen. http://www.diabetes.co.uk/insulin/basal-bolus.html. Accessed June 14, 2014.
  10. Global Guideline for Type 2 Diabetes. International Diabetes Federation, 2012, Clinical Guidelines Task Force. http://www.idf.org/global-guideline-type-2-diabetes-2012. Accessed June 12, 2014.
  11. Funnel MM. Overcoming barriers to the initiation of insulin therapy. Clin Diabetes. 2007;25(1):36-38.
  12. American Diabetes Assoication. A1C and eAG. http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/a1c/. Accessed June 12, 2014.
  13. Monnier L Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care. 2003;26(3):881-885.

Discover how NovoLog® works in the body to control blood sugar.

Selected Important Safety Information

Contraindications

  • NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. 

Warnings and Precautions

  • Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. 
  • Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased.

NovoLog® (insulin aspart injection) 100 U/mL Indications and Usage

NovoLog® (insulin aspart injection) 100 U/mL is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. 

Important Safety Information

Contraindications

  • NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. 

Warnings and Precautions

  • Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. 
  • Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. 
  • Hypoglycemia is the most common adverse effect of insulin therapy. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. 
  • To avoid medication errors and accidental mix-ups between NovoLog® and other insulin products, instruct patients to always check the insulin label before injection. 
  • Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with insulin products, including NovoLog®
  • As with all insulins, NovoLog® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death.  Monitor potassium levels in patients at risk for hypokalemia and treat if indicated.
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including NovoLog®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered. 
  • Malfunction of the insulin pump or insulin infusion set or insulin degradation can rapidly lead to hyperglycemia and ketoacidosis. Patients using insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure. 

NovoLog® continuous subcutaneous infusion route (insulin pump): Do not mix NovoLog® with any other insulin or diluent. 

Adverse Reactions

  • Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. 

Use in Specific Populations

  • NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes who are younger than 2 years of age. 
  • Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment. These patients may require more frequent blood glucose monitoring and dose adjustments. 

Please click here for Prescribing Information.